BiotechTube

Zopapogene imadenovec (Zopa)

ApprovedRecruiting
0 watching 0 views this week🔥 Hot
80
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Recurrent Respiratory Papillomatosis

Conditions

Recurrent Respiratory Papillomatosis, Papillomavirus Infection, Papillomaviridae

Trial Timeline

Jul 11, 2024 → Dec 2, 2028

NCT ID
NCT06538480

About Zopapogene imadenovec (Zopa)

Zopapogene imadenovec (Zopa) is a approved stage product being developed by Precigen for Recurrent Respiratory Papillomatosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06538480. Target conditions include Recurrent Respiratory Papillomatosis, Papillomavirus Infection, Papillomaviridae.

Hype Score Breakdown

Clinical
30
Activity
20
Company
5
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT06538480ApprovedRecruiting

Competing Products

20 competing products in Recurrent Respiratory Papillomatosis

See all competitors
ProductCompanyStageHype Score
KPL-914Kiniksa PharmaceuticalsPhase 2
47
KPL-387Kiniksa PharmaceuticalsPhase 2
47
Rilonacept + PlaceboKiniksa PharmaceuticalsPhase 3
72
Enzastaurin (LY317615) + CarboplatinEli LillyPhase 1
33
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2PrecigenPhase 1/2
36
[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPerspective TherapeuticsPhase 1/2
33
Ramucirumab + PembrolizumabEli LillyPhase 2
52
Gemcitabine and UFTE chemotherapyYuhanPhase 2
52
Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + PembrolizumabDaiichi SankyoPhase 1/2
41
Ifinatamab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab DeruxtecanDaiichi SankyoPhase 1
33
PLX3397Daiichi SankyoPhase 2
52
erlotinib + etoposideAstellas PharmaPhase 2
52
Drug Combination TherapySun PharmaceuticalPhase 2
52
Niraparib + AnlotinibSun PharmaceuticalPhase 2
52
Eribulin MesylateEisaiPre-clinical
23
Lenvatinib + EverolimusEisaiPhase 1/2
41
E7090EisaiPhase 2
52
LenvatinibEisaiPhase 2
52
Eribulin mesilate + Irinotecan hydrochlorideEisaiPhase 1/2
41

Other Products from Precigen

PRGN-2009 plus Pembrolizumab + Pembrolizumab alonePhase 2
47
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2Phase 1/2
36
AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High DosePhase 1/2
36
INXN-4001Phase 1
28
Fludarabine + Cyclophosphamide + PRGN-3007Phase 1
28